Madhya Pradesh Online Journal

Implantable Cardioverter Defibrillators Pipeline Insight and Competitive Landscape, 2022

 Breaking News
  • No posts were found

Implantable Cardioverter Defibrillators Pipeline Insight and Competitive Landscape, 2022

June 09
01:08 2022
Implantable Cardioverter Defibrillators Pipeline Insight and Competitive Landscape, 2022

DelveInsight’s, Implantable Cardioverter Defibrillators Pipeline Insight and Competitive Landscape, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in the Implantable Cardioverter Defibrillators (ICD) pipeline landscape. The defibrillator market is witnessing various technological advancements and product innovations.

 

Implantable Cardioverter Defibrillators (ICD): An Overview

Defibrillation is used for patients suffering from life-threatening conditions which affect the heart’s rhythm such as cardiac arrhythmia, ventricular fibrillation, and pulseless ventricular tachycardia. Defibrillators help in delivering an electrical shock or sending an electrical impulse to the heart, thus causing depolarization of the heart muscles and maintaining the normal conduction of the heart’s impulse. They can also be used to restore the heartbeat in case the heart stops functioning.

 

Download a sample copy of the report @ https://www.delveinsight.com/sample-request/implantable-cardioverter-defibrillators-pipeline-insight

 

Implantable Cardioverter Defibrillators Insights

The market for defibrillators is rising with the increasing cases of arrhythmia due to the high prevalence of heart diseases, aging population, smoking, high blood pressure, high cholesterol, etc. Defibrillators can prevent sudden death among people who have a high risk of life-threatening arrhythmia.

 

Implantable Cardioverter Defibrillators Types

These are different type of defibrillators that are used to assist people in case of a sudden cardiac arrest or arrhythmia. Automated Cardioverter Defibrillator is a light-weight, battery operated and portable device that works by checking the rhythm of the heart and sends a shock to the heart in order to restore the normal heartbeat. Implantable Cardioverter Defibrillators are used in patients suffering from cardiac, which obstruct the flow of the blood from the heart to the rest of the body.

Therefore, the device is surgically implanted in the chest/ abdomen that can send a shock to correct arrhythmia. Wearable Cardioverter Defibrillators have sensors attached with the skin. These are connected by the help of wires to a unit which keeps a check on the rhythm of the heat and corrects it by sending a shock.

 

Implantable Cardioverter Defibrillators Competitive Assessment

This segment of the Implantable Cardioverter Defibrillators (ICD) report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development. 

 

By Product Type

Implantable Cardioverter Defibrillators (ICD) can divided based on Types – Implantable Cardioverter Defibrillator, External Defibrillator- are covered in this report. 

 

By Application

Implantable Cardioverter Defibrillators (ICD) can be divided based on application – Bradycardia, Tachycardia, Heart Failure, & Others

 

To Get More Details of the Report @ https://www.delveinsight.com/sample-request/implantable-cardioverter-defibrillators-pipeline-insight

 

Recent Development Activities of the Implantable Cardioverter Defibrillators Report

  • In January 2020, Abbott received CE Mark for its new implantable cardioverter defibrillator, Gallant, and cardiac resynchronization therapy defibrillator devices. The devices offer a patient preferred design having smartphone connectivity, connected applications, improved battery longevity and MRI compatibility.
  • In June 2020, Philips received FDA approval for its two new automated external defibrillators, HeartStart FR3 and HeartStart FRx. The HeartStart FR3 is an advanced device designed for use by medical professionals, having features such as “quick shock” to minimize hands-off time. On the other hand, The HeartStart FRx is designed to be applied by bystanders to those nearby. It provides voice guidance on how to perform CPR properly, as well as a ticking metronome to help guide chest compressions.

 

Implantable Cardioverter Defibrillators Companies

  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corp
  • MicroPort Scientific Corp
  • Biotronik SE & Co. KG
  • Cintas Corp, and several others

 

Table of Content

1. Key Insights

2. Snapshot

3. Implantable Cardioverter Defibrillators (ICD)

4. Competitive Assessment

5. Competitive Benchmarking: By Company

6. Commercialization Activity

7. Regulatory

8. Reimbursement

9. Market Dynamics

10. DelveInsight’s Analytical Perspective

11. Conclusion

12. Appendix 

13. Bibliography

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/